AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2024
Feb 13, 2024
30604_dirs_2024-02-13_4b1cb6c5-07ac-42ea-963d-cda5ef18f829.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2023-12-31
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-28 | Common Stock | P | 1891 | $13.18 | Acquired | 1891 | Indirect |
| 2021-12-28 | Common Stock | P | 1542 | $12.68 | Acquired | 3433 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1764 | Direct |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3